Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

EU court adviser backs EU antitrust fine on Lundbeck

Published 06/04/2020, 04:15 AM
Updated 06/04/2020, 04:20 AM
© Reuters.
LUN
-

BRUSSELS (Reuters) - An adviser to Europe's top court on Thursday said the court should uphold an EU antitrust fine imposed on Danish drugmaker Lundbeck (CO:LUN) for its deals with rivals to delay sales of generic copies of its anti-depressant citalopram.

The European Commission had fined Lundbeck and five other generic drugmakers in 2013 a combined 146 million euros for their "pay-for-delay" deals because they breached EU rules.

Lundbeck's fine was 93.7 million euros ($104.95 million). The company subsequently challenged the EU antitrust decision at the General Court but lost in 2016, prompting it to appeal to the EU Court of Justice, Europe's highest.

The case is C-591/16 P Lundbeck v Commission.

($1 = 0.8928 euros)

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.